This invention concerns a pharmaceutically-acceptable composition of radioactive metals, which are used for treating various diseases in animals or humans, such as cancer and arthritis.

The disclosure relates to compositions comprising isolated mitochondria or combined mitochondrial agents, and methods of treating disorders using such compositions.

A brachytherapy device (20, 21) including a base (22) adapted for being at least partially introduced into a body of a subject and a plurality of radionuclide atoms of a first alpha-emitting isotope, coupled to the base in a manner that not more than 15% of the radionuclide atoms leave the base in 24 hours, in methods other than radioactive decay. When installed in a human subject, the brachytherapy device emits radionuclide atoms of the first alpha-emitting isotope at a rate of at least 0.1% of the number of radionuclide atoms of the first alpha-emitting isotope coupled to the base, per 24 hours.

The invention describes method for delivering and positioning radio-isotopes. The method uses encapsulating free flowing medicament into a leak proof vehicle and positioning the vehicle into the body. Also provided is a system for delivering and positioning radio-isotopes into the body, the system comprising fluid radio-isotope encapsulated in a leak proof material and/or absorbable material.

An infusion system may include a strontium-rubidium radioisotope generator that generates a radioactive eluate via elution, a beta detector, a gamma detector, and a controller. The beta detector and the gamma detector may be positioned to measure beta emissions and gamma emissions, respectively, emitted from the radioactive eluate. In some examples, the controller is configured to determine an activity of rubidium in the radioactive eluate based on the beta emissions measured by the beta detector and determine an activity of strontium in the radioactive eluate based on the gamma emissions measured by the gamma detector.

A shielding assembly may be used in a nuclear medicine infusion system that generates and infuse radioactive liquid into a patient undergoing a diagnostic imaging procedure. In some examples, the shielding assembly has multiple compartments each formed of a shielding material providing a barrier to radioactive radiation. For example, the shielding assembly may have a first compartment configured to receive a radioisotope generator that generates a radioactive eluate via elution, a second compartment configured to receive a beta detector, and a third compartment configured to receive a gamma detector. In some examples, the compartments are arranged to minimize background radiation emitted by the radioisotope generator and detected by the gamma detector to enhance the quality of the measurements made by the gamma detector.

The present invention provides a method for the purification of .sup.227Th from a mixture comprising .sup.227Th and .sup.223Ra, said method comprising: i) preparing a first solution comprising a mixture of .sup.227Th and .sup.223Ra ions dissolved in an aqueous solution of first mineral acid; ii) loading said first solution onto a strong base anion exchange resin; iii) eluting .sup.223Ra from said strong base anion exchange resin using a second mineral acid in an aqueous solution; iv) optionally rinsing said strong base anion exchange resin using a first aqueous medium; v) eluting .sup.227Th from said strong base anion exchange resin using a third mineral acid in an aqueous solution whereby to generate a second solution comprising .sup.227Th. The invention further provides a purified .sup.227Th solution, a corresponding pharmaceutical formulation and methods of treatment of neoplastic disease.

A dual double balloon catheter includes a catheter having a proximal end portion, a central portion and a distal end portion, and a secondary treatment balloon for a catheter. The catheter includes a plurality of lumens within the catheter extending from the proximal end portion, a plurality of inflatable balloons positioned in the central portion and a secondary treatment balloon communicatively associated with the distal end portion of the catheter, and the balloons and the secondary treatment balloon being communicatively connected with a corresponding one of the plurality of lumens to selectively inflate/deflate the corresponding inflatable balloon or to receive a radioactive dose or a therapeutic agent for a treatment.

This invention concerns a pharmaceutically-acceptable composition of radioactive metals, which are used for treating various diseases in animals or humans, such as cancer and arthritis.

Effective treatments of pain and/or inflammation are provided. Through the administration of a porous biodegradable drug depot film, patch, strip or sponge being implantable within a nasal or sinus cavity and having pores sized to prevent the depot from functioning as a scaffold for tissue growth, one can reduce, prevent or treat pain and/or inflammation and prevent cells from infiltrating the drug depot and laying down scaffolding cells.